Literature DB >> 24790136

Rap1b in smooth muscle and endothelium is required for maintenance of vascular tone and normal blood pressure.

Sribalaji Lakshmikanthan1, Bartosz J Zieba1, Zhi-Dong Ge1, Ko Momotani1, Xiaodong Zheng1, Hayley Lund1, Mykhaylo V Artamonov1, Jason E Maas1, Aniko Szabo1, David X Zhang1, John A Auchampach1, David L Mattson1, Avril V Somlyo1, Magdalena Chrzanowska-Wodnicka2.   

Abstract

OBJECTIVE: Small GTPase Ras-related protein 1 (Rap1b) controls several basic cellular phenomena, and its deletion in mice leads to several cardiovascular defects, including impaired adhesion of blood cells and defective angiogenesis. We found that Rap1b(-/-) mice develop cardiac hypertrophy and hypertension. Therefore, we examined the function of Rap1b in regulation of blood pressure. APPROACH AND
RESULTS: Rap1b(-/-) mice developed cardiac hypertrophy and elevated blood pressure, but maintained a normal heart rate. Correcting elevated blood pressure with losartan, an angiotensin II type 1 receptor antagonist, alleviated cardiac hypertrophy in Rap1b(-/-) mice, suggesting a possibility that cardiac hypertrophy develops secondary to hypertension. The indices of renal function and plasma renin activity were normal in Rap1b(-/-) mice. Ex vivo, we examined whether the effect of Rap1b deletion on smooth muscle-mediated vessel contraction and endothelium-dependent vessel dilation, 2 major mechanisms controlling basal vascular tone, was the basis for the hypertension. We found increased contractility on stimulation with a thromboxane analog or angiotensin II or phenylephrine along with increased inhibitory phosphorylation of myosin phosphatase under basal conditions consistent with elevated basal tone and the observed hypertension. Cyclic adenosine monophosphate-dependent relaxation in response to Rap1 activator, Epac, was decreased in vessels from Rap1b(-/-) mice. Defective endothelial release of dilatory nitric oxide in response to elevated blood flow leads to hypertension. We found that nitric oxide-dependent vasodilation was significantly inhibited in Rap1b-deficient vessels.
CONCLUSIONS: This is the first report to indicate that Rap1b in both smooth muscle and endothelium plays a key role in maintaining blood pressure by controlling normal vascular tone.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  relaxation; signal transduction; vasodilation

Mesh:

Substances:

Year:  2014        PMID: 24790136      PMCID: PMC4224284          DOI: 10.1161/ATVBAHA.114.303678

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  54 in total

1.  Cyclic AMP-independent involvement of Rap1/B-Raf in the angiotensin II AT2 receptor signaling pathway in NG108-15 cells.

Authors:  Louis Gendron; Jean-Francois Oligny; Marcel Daniel Payet; Nicole Gallo-Payet
Journal:  J Biol Chem       Date:  2002-12-02       Impact factor: 5.157

2.  Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho.

Authors:  T Matsui; M Amano; T Yamamoto; K Chihara; M Nakafuku; M Ito; T Nakano; K Okawa; A Iwamatsu; K Kaibuchi
Journal:  EMBO J       Date:  1996-05-01       Impact factor: 11.598

3.  The 1996 Albert Lasker Medical Research Awards. The discovery of endothelium-derived relaxing factor and its importance in the identification of nitric oxide.

Authors:  R F Furchgott
Journal:  JAMA       Date:  1996-10-09       Impact factor: 56.272

4.  Cardiac hypertrophy in spontaneously hypertensive rats.

Authors:  S Sen; R C Tarazi; P A Khairallah; F M Bumpus
Journal:  Circ Res       Date:  1974-11       Impact factor: 17.367

5.  Elevated blood pressures in mice lacking endothelial nitric oxide synthase.

Authors:  E G Shesely; N Maeda; H S Kim; K M Desai; J H Krege; V E Laubach; P A Sherman; W C Sessa; O Smithies
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

6.  Effects of lisinopril vs hydralazine on left ventricular hypertrophy and ambulatory blood pressure monitoring in essential hypertension.

Authors:  R Fogari; A Zoppi; A Mugellini; F Tettamanti; P Lusardi; L Corradi
Journal:  Eur Heart J       Date:  1995-08       Impact factor: 29.983

7.  Hypertension in mice lacking the gene for endothelial nitric oxide synthase.

Authors:  P L Huang; Z Huang; H Mashimo; K D Bloch; M A Moskowitz; J A Bevan; M C Fishman
Journal:  Nature       Date:  1995-09-21       Impact factor: 49.962

Review 8.  Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase.

Authors:  Andrew P Somlyo; Avril V Somlyo
Journal:  Physiol Rev       Date:  2003-10       Impact factor: 37.312

9.  Vasodilators and regression of left ventricular hypertrophy. Hydralazine versus prazosin in hypertensive humans.

Authors:  F H Leenen; D L Smith; R M Farkas; R A Reeves; A Marquez-Julio
Journal:  Am J Med       Date:  1987-05       Impact factor: 4.965

10.  Rho-stimulated contractility drives the formation of stress fibers and focal adhesions.

Authors:  M Chrzanowska-Wodnicka; K Burridge
Journal:  J Cell Biol       Date:  1996-06       Impact factor: 10.539

View more
  26 in total

1.  Circular RNAs in rat models of cardiovascular and renal diseases.

Authors:  Xi Cheng; Bina Joe
Journal:  Physiol Genomics       Date:  2017-08-04       Impact factor: 3.107

2.  Leukocyte transcellular diapedesis: Rap1b is in control.

Authors:  Marie-Dominique Filippi
Journal:  Tissue Barriers       Date:  2015-05-21

3.  Differential mechanisms of adenosine- and ATPγS-induced microvascular endothelial barrier strengthening.

Authors:  Róbert Bátori; Sanjiv Kumar; Zsuzsanna Bordán; Mary Cherian-Shaw; Anita Kovács-Kása; Justin A MacDonald; David J R Fulton; Ferenc Erdődi; Alexander D Verin
Journal:  J Cell Physiol       Date:  2018-12-17       Impact factor: 6.384

4.  Extracellular adenosine-induced Rac1 activation in pulmonary endothelium: Molecular mechanisms and barrier-protective role.

Authors:  Anita Kovacs-Kasa; Kyung Mi Kim; Mary Cherian-Shaw; Stephen M Black; David J Fulton; Alexander D Verin
Journal:  J Cell Physiol       Date:  2018-03-07       Impact factor: 6.384

Review 5.  Intracellular cAMP Sensor EPAC: Physiology, Pathophysiology, and Therapeutics Development.

Authors:  William G Robichaux; Xiaodong Cheng
Journal:  Physiol Rev       Date:  2018-04-01       Impact factor: 37.312

Review 6.  AT1 receptor signaling pathways in the cardiovascular system.

Authors:  Tatsuo Kawai; Steven J Forrester; Shannon O'Brien; Ariele Baggett; Victor Rizzo; Satoru Eguchi
Journal:  Pharmacol Res       Date:  2017-05-17       Impact factor: 7.658

Review 7.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

8.  Rap1 promotes endothelial mechanosensing complex formation, NO release and normal endothelial function.

Authors:  Sribalaji Lakshmikanthan; Xiaodong Zheng; Yoshinori Nishijima; Magdalena Sobczak; Aniko Szabo; Jeannette Vasquez-Vivar; David X Zhang; Magdalena Chrzanowska-Wodnicka
Journal:  EMBO Rep       Date:  2015-03-25       Impact factor: 8.807

Review 9.  Rap1 in endothelial biology.

Authors:  Magdalena Chrzanowska-Wodnicka
Journal:  Curr Opin Hematol       Date:  2017-05       Impact factor: 3.284

10.  Kv7 Channel Activation Underpins EPAC-Dependent Relaxations of Rat Arteries.

Authors:  Jennifer B Stott; Vincenzo Barrese; Iain A Greenwood
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-10-27       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.